Chan Yoon Cheah
Professor, Consultant Haematologist
Sir Charles Gairdner Hospital / University of Western Australia · Perth, Australia
Australian MCL expert with significant contributions to BTK inhibitor research and novel agent clinical trials for MCL.
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
Leukemia & lymphoma · Mar 17, 2026
Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape.
Expert review of hematology · Mar 1, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
Recent advances and future directions in newly diagnosed mantle cell lymphoma.
Expert opinion on pharmacotherapy · Sep 1, 2025
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.
Haematologica · Mar 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Internal medicine journal · Jan 1, 2025
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.
Nature reviews. Clinical oncology · Dec 1, 2024
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood · Feb 22, 2024
Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
British journal of haematology · Feb 1, 2024